Total Neoadjuvant Therapy (TNT) in Rectal Cancer: A Comprehensive Review

Evolution of Rectal Cancer Treatment

• 💡 The treatment for locally advanced rectal cancer (LARC) has evolved significantly, with Total Neoadjuvant Therapy (TNT) now a routine clinical practice.
• 🎯 LARC is defined by specific T and N stages, including T3/T4 tumors and node-positive disease, qualifying patients for TNT.
• 🔑 European guidelines consider TNT for high-risk tumors, defined by factors like clinical T4, concern for mesorectal fascia involvement, N2 disease, positive EMVI, or large lateral lymph nodes.

Historical Context and Rationale for TNT

• 🔬 Early rectal cancer trials (Swedish, Dutch) established the benefit of neoadjuvant radiation and standardized Total Mesorectal Excision (TME).
• 📈 The AIO 94 and NSABP RO3 trials demonstrated that preoperative chemoradiation reduced local recurrence and toxicities.
• ⚠️ A key lesson from the Endorse trial was that many patients couldn't complete adjuvant chemotherapy post-surgery, leading to concerns about micrometastatic disease progression.
• ⏳ Trials investigating delayed surgery after short-course radiation showed a significant increase in pathologic complete response (pCR), highlighting the value of time for tumor regression.
• 🚀 TNT aims to deliver all systemic therapy and radiation before surgery, ensuring patients receive intended treatments, addressing micrometastases earlier, and improving response rates.

Landmark TNT Trials and Outcomes

• 📊 The RAPIDO trial used short-course radiation followed by chemotherapy (FOLFOX/CAPOX), showing doubled pCR rates but also a higher local-regional failure rate, questioning the short-course approach.
• 📈 The PRODIGE-23 trial utilized induction chemotherapy (FOLFOX) followed by chemoradiation, demonstrating improved disease-free survival, overall survival, and metastasis-free survival at seven years.
• ✅ These trials confirmed the safety and efficacy of TNT, leading to higher pCR rates and paving the way for organ preservation strategies.

Organ Preservation and Watch-and-Wait Strategies

• 🎯 The OPRA trial investigated organ preservation in LARC patients treated with TNT, offering a watch-and-wait (WW) approach for those achieving a clinical complete response (cCR).
• 💡 Approximately 50% of patients achieved sustained cCR and organ preservation, with equivalent survival rates to historical TME controls.
• ⚠️ Regrowth during surveillance occurred primarily within the first two years, emphasizing the need for close monitoring.
• 🧩 Patients with a near-complete response (nCR) had a higher rate of regrowth but still achieved sustained organ preservation in over half of cases.
• 🏥 The CAO/ARO/AIO 12/16 trials explored different TNT sequences (induction vs. consolidation chemotherapy) and demonstrated superior pCR rates with consolidation chemotherapy, highlighting the importance of TNT sequencing.
• 🌟 A pooled analysis of the CAO/ARO/AIO 12 and OPRA trials showed comparable DFS and OS between patients with nCR and those with intermediate pathological response, supporting WW for nCR patients.

Emerging Research and Future Directions

• 🔬 Immunotherapy is being investigated, particularly for mismatch repair proficient (MSS) tumors, with novel agents like botensilimab showing promise.
• 🧬 The role of circulating tumor DNA (ctDNA) in surveillance and response prediction is under active investigation, though not yet ready for clinical decision-making.
• ☢️ Research is exploring optimizing radiation techniques, such as focusing on the primary tumor to potentially spare lymph nodes and reduce lymphopenia, especially in the context of immunotherapy.
• 🚀 Future trials aim to integrate chemoradiotherapy, chemotherapy, and immunotherapy to further deescalate treatment, increase complete response rates, and expand organ preservation options.